Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PLEC | Q15149 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27265453 | 0.82 | EPHX1 (0.42) | ALDH1A1EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL20899758 | 0.78 | KDM4E (0.31) | KDM4EMAPTTP53GAATHRB | |
| SCHEMBL23571 | 0.78 | PDK1 (0.32) | ALDH1A1KDM4EMAPTTP53GAA | |
| SCHEMBL14926868 | 0.77 | EPHX1 (0.39) | ALDH1A1EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL23515873 | 0.76 | L3MBTL1 (0.36) | CA2L3MBTL1PKM | |
| SCHEMBL13830424 | 0.76 | CRBN (0.32) | CA2NFKB1 | |
| SCHEMBL3810514 | 0.76 | GRM5 (0.31) | — | |
| SCHEMBL14446732 | 0.74 | EPHX1 (0.37) | ALDH1A1EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL22702459 | 0.74 | KDM5B (0.35) | — | |
| SCHEMBL13829831 | 0.74 | MAPT (0.35) | ALDH1A1KDM4EMAPTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | NUVATION BIO INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3985010-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021222466-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021160617-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2021-08-19 | — | — | WO | disclosed |
| EP-3865489-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2021-08-18 | — | — | EP | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| WO-2021003310-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | BET1, BRD4, BRD3 | ALDH1A1 4239/4885EPHX1 1535/4885KDM4E 555/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ALDH1A1 1598/4885EPHX1 3246/4885KDM4E 1101/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | ALDH1A1 4239/4885EPHX1 1535/4885KDM4E 555/4885 |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | ALDH1A1 4239/4885EPHX1 1535/4885KDM4E 555/4885 |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | ALDH1A1 541/4885EPHX1 4366/4885KDM4E 2869/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ALDH1A1 1598/4885EPHX1 3246/4885KDM4E 1101/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALDH1A1 1601/4885EPHX1 3390/4885KDM4E 1086/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALDH1A1 1598/4885EPHX1 3246/4885KDM4E 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.